News
Hamburg/Germany, August 25, 2010 – CYTAVIS BioPharma currently is conducting a Phase II trial with its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma. Already, more than 20 German study centers are participating in the trial.
Read more …
25.08.2010 (09:00) by Administrator
Hamburg/Germany, August 20, 2010 – CYTAVIS BioPharma today annonced the completion of a phase II trial with its lead compound Aviscumine (CY-503) in patients with refractory metastatic melanoma (stage IV). The study comprising 32 patients was conducted at four German sites (Hauttumorcentrum Charité Berlin Dermatologisches Zentrum Buxtehude / Elbe Klinikum, Haut-Tumor-Zentrum Hannover, Universitäts-Hautklinik Kiel) and is currently being evaluated.
Read more …
20.08.2010 (09:00) by Administrator
Hamburg/Germany, September 14, 2009 – Cytavis GmbH, a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological and immunological diseases, today announced the start of a Phase II trial with its lead compound Aviscumine (CY-503) in patients with chemotherapy-refractory metastatic colorectal carcinoma (NCT 00932724)
Read more …
14.09.2009 (10:34) by Administrator
CYTAVIS BioPharma is currently conducting a phase II trial with Aviscumine (CY-503) in patients with metastatic melanoma (stage IV).
Read more …
01.04.2009 (12:09) by Administrator
